Pharmaceutical firm raises £4m to fund launch of children’s anti-drooling drug
Manchester-based paediatric pharmaceutical company Proveca has raised £4m to fund the commercial launch of Sialanar, a treatment for chronic pathological drooling in children, and for the development and commercialisation of its paediatric product portfolio.
Sialanar has been launched in the UK by Proveca, to be followed by the rest of Europe.
The investment was led by Catapult Ventures, managers of the GM&C Life Sciences Fund, alongside Kreos Capital, a leading European provider of growth debt financing, and will enable Pr... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
